7 Results for "

Fluid retention

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "Fluid retention" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-10199A
CAS No.: 159634-47-6
Purity:  98.52%
Synonyms: MK-677 free base; MK-0677 free base
Ibutamoren (MK-677 free base; MK-0677 free base) is an orally active non-peptide growth hormone secretagogue receptor agonist. Ibutamoren activates signal cascades by mimicking endogenous ligands, triggers pulsatile release of growth hormone from the pituitary gland, and increases serum levels of IGF-1 and insulin-like growth factor-binding protein 3. Ibutamoren not only increases the frequency of growth hormone pulses in male individuals, but also promotes elevated bone formation markers in female individuals with postmenopausal osteoporosis. The combination of Ibutamoren with Alendronate sodium hydrate (HY-11101) significantly increases bone mineral density at the femoral neck. However, Ibutamoren may cause mild, reversible adverse reactions such as increased appetite, fluid retention, and elevated fasting blood glucose. Ibutamoren has been widely used in studies related to idiopathic growth hormone deficiency, sarcopenia, Alzheimer's disease, and osteoporosis .
loading...
    loading...
Cat. No.: HY-15195
CAS No.: 290815-26-8
Purity:  98.15%
Synonyms: Ro 67-0565; SPP-301
Target:  

Endothelin Receptor

Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure .
loading...
    loading...
Cat. No.: HY-141573
CAS No.: 143-28-2
Purity:  84.00%
Research Areas:  

Neurological Disease Cancer

Oleyl alcohol is an anti-tumor compound that inhibits tumor growth. Oleyl alcohol induces cytotoxicity, cell death and apoptosis. The intracellular accumulation of Oleyl alcohol correlates with its cytotoxicity against tumor cells. Oleyl alcohol forms enhancer-enriched fluid domains in stratum corneum lipids, increases the retention of diclofenac diethylamine in ex vivo human epidermis and dermis, and enhances the skin permeability of diclofenac diethylamine. Oleyl alcohol can be used in studies related to neuroblastoma .
loading...
    loading...
Cat. No.: HY-D1005A7
CAS No.: 9003-11-6
Synonyms: PEG-PPG-PEG, 2400 (Average)
Poloxamer 125 (L45) (PEG-PPG-PEG, 2400 (Average)) is a block polymer of polyoxyethylene and polyoxypropylene, belonging to water-soluble non-ionic biosurfactants with properties such as emulsification and wetting. Poloxamer 125 (L45) has thermosensitive characteristics and can form thermoreversible hydrogels in aqueous solutions, presenting a fluid state at room temperature and transforming into a viscous gel under body temperature conditions; when its concentration is higher than the critical micelle concentration, it can also self-assemble into micelles in aqueous systems. Poloxamer 125 (L45) enables controlled drug release, prolongs the local retention time of drugs, and is often used as a drug delivery carrier. Poloxamer 125 (L45) can be applied in the fields of cosmetics, biomedicine and tissue engineering .
loading...
    loading...
Cat. No.: HY-178958
CAS No.: 3122526-69-3
PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, PPARα (EC50 = 1.51 μM), PPARδ (EC50 = 1.11 μM), and PPARγ (EC50 = 3.14 μM). PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD)/ Streptozotocin (HY-13753) (STZ)-induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes .
loading...
    loading...
Cat. No.: HY-120147
CAS No.: 1824-58-4
Ethiazide is a thiazole diuretic which inhibits renal reabsorption of sodium and water, thereby increasing urine excretion, reducing fluid retention, and lowering blood volume and blood pressure. Ethiazide can be used for cardiovascular research .
loading...
    loading...
Cat. No.: HY-15195R
CAS No.: 290815-26-8
Synonyms: Ro 67-0565 (Standard); SPP-301 (Standard)
Avosentan (Standard) is the analytical standard of Avosentan (HY-15195). This product is intended for research and analytical applications. Avosentan is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction, and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.
loading...
    loading...